Definitive contract 75F40121C00121DYNAMO TECHNOLOGIES, LLC
Overview
Award facts
- Net obligations
- $1.96M
- $1,957,250of $1.96M potential value
- Outlays (paid to date)
- $1.96M
- $1.96M paid of $1.96M obligated$1,957,250
- Period of performance
- Aug 30, 2021 to Aug 5, 2022
- Ended
- Modifications
- 1
- Latest action Nov 8, 2024
- Contract type
- Definitive contract
- PIID 75F40121C00121
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
LABOR HOUR AWARD CENTER FOR DRUG EVALUATION AND RESEARCH (CDER) - IT INVESTMENT MANAGEMENT SUPPORT FDA THREE-WAY-MATCHING INVOICE CLAUSE-COR: EKATERINA.LEISTNER@FDA.HHS.GOV NOTICE TO PROCEED WAS GIVEN ON 08/03/2021 EFFECTIVE 08/06/2021.
Dates and value
- Award date
- Signed on Aug 30, 2021
- Potential end of performance
- Aug 4, 2022
- Current value
- $1,957,250Base and exercised options
- Potential value (if all options are exercised)
- $1,957,250
Obligations by fiscal year of action
- FY2025: -$1,594 (de-obligation)
- FY2021: $1,958,844
Total across 2 fiscal years: $1,957,250
Net de-obligation in that fiscal year (obligations withdrawn).
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Nov 8, 2024. View on USAspending · Recipient on SAM.gov
Recipient
Business types and certifications
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- Food And Drug Administration
- FDA OFFICE OF ACQ GRANT SVCS
- Funded by
- Department of Health and Human Services
- Food And Drug Administration
- FDA OFFICE OF ACQ GRANT SVCS
- Funded from
- Human drugs; Coronavirus emergency funding supplemental; Fda user fees (non general fund)Program activities075-0600Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Rockville, Montgomery County, Maryland 20857-0001
- Congressional district (place of performance)
- MD-08As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- R408SUPPORT- PROFESSIONAL: PROGRAM MANAGEMENT/SUPPORT (service)
Competition
- Extent competed
- Not competedC
- Reason not competed
- Only one source-other (FAR 6.302-1 other)ONE
- Solicitation procedures
- Only one sourceSSS
- Set-aside
- No set-aside used
- Contract pricing
- Labor hoursZ
- Offers received
- 1
Contract details
- Subcontracting plan
- Plan not requiredB
- Major program
- Center for drug evaluation and research (CDER) - IT investment management support
- Cost Accounting Standards clause
- Yes - CAS clause includedY
- Certified cost or pricing data
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Aug 30, 2021Base obligation at award: $1,958,844
- Latest action
- Nov 8, 2024 — CloseoutModification P00001; obligation change -$1,594; administrative: no change in scope or value
- Actions by type
- Base award1
- Closeout1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
- Latest action: change in base and exercised options
- -$1,594
- Latest action: change in base and all options
- -$1,989,821
Socio-economic and policy
- Inherently governmental functions
- Closely associatedCL
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7524
- Contracting office code
- 75F401
- Transactions recorded under this award key
- 2
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7524
- Funding office code
- 75F401
- Treasury accounts
- 075-2021/2021-0600-000
- 075-X-0600-000
- Object classes
- 25.2: Other services from non-Federal sources
- Disaster or emergency funding (DEFC)
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression
- V: Non-emergency P.L. 117-2
- COVID-19 supplemental obligations
- $199,858
- COVID-19 supplemental outlays
- $199,858